Semaglutide is the active ingredient in the brand-name medications Ozempic and Wegovy
Shrimanker, I., & Bhattarai, S
To view or add a comment, sign in Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 Samjin Pharmaceutical (hereinafter referred to as Samjin Pharm) announced on February 4 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial of SJN314 (development code). The candidate represents a key asset within the company's novel drug research pipeline focused on Inflammation & Immunology. SJN314 is an orally administered, small-molecule inhibitor of Mas-related G-protein-coupled receptor X2 (MRGPRX2), being developed for the treatment of inflammatory conditions such as chronic spontaneous urticaria (CSUR) and atopic dermatitis
In that way, you can guarantee flawless-looking skin and healthy well-being!
For protein help, read getting enough protein on GLP-1
Sirtuins and NAD(+) in the development and treatment of metabolic and cardiovascular diseases